drugset / Trial / NCT00139737
Extension Study: Evaluating the Safety of Oral Ziprasidone in the Treatment of Subjects With Schizophrenia
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To provide treatment to eligible subjects who have successfully completed one of the following phase III ziprasidone studies, A1281028, A1281044, A1281045 (NCT00136994) or A1281088 (NCT00143351).
Timeline
- Start
- 2002-03
- Primary completion
- 2009-06
- Completion
- 2009-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ziprasidone | Small molecule | 20 mg | Oral |
| Subject | Ziprasidone | Small molecule | 40 mg | Oral |
| Subject | Ziprasidone | Small molecule | 60 mg | Oral |
| Subject | Ziprasidone | Small molecule | 80 mg | Oral |